Why the study?
Is bedaquiline associated with adverse cardiac safety events such as QT extension in patients with MDR or XDR tuberculosis?
Population
Patients with multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB)
Design
Systematic_review
Authors
Loading...
Bedaquiline appears to have an acceptable cardiac safety profile in the treatment of drug-resistant tuberculosis, with QT prolongation leading to discontinuation in only a minority of patients.
Is bedaquiline associated with adverse cardiac safety events such as QT extension in patients with MDR or XDR tuberculosis?
Bedaquiline appears to have an acceptable cardiac safety profile in the treatment of drug-resistant tuberculosis, with QT prolongation leading to discontinuation in only a minority of patients.
Pontali et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: